期刊文献+

直肠癌新辅助治疗后病理分期状况与生存预后的关系 被引量:13

Postoperative pathological staging correlates the prognosis of rectal cancer after neoadjuvantchemoradiotherapy
原文传递
导出
摘要 目的研究新辅助治疗后直肠癌的术后病理分期特征与患者3年无病生存期(DFS)的关系。方法回顾分析2005年1月至2012年12月接受新辅助治疗的直肠癌患者术后生存情况,研究肿瘤浸润深度、淋巴结状况、局部浸润因素(切缘、癌结节、血管神经浸润等)、TNM分期与DFS的关系。结果共人选135例患者,其中男性79例,女性56例,平均年龄(58±12)岁(18-80岁)。患者总体3年DFS为85.2%,完全病理缓解率(pCR)为19.3%,ypTON+者3例,占ypT0患者的10.4%。随着ypT分期和ypTNM分期的进展,DFS有下降的趋势(x。=14.296、52.643,P=0.006、0.000);ypT0-T2期和yp0-I期的患者有较好的DFS(分别为93.1%-100%和92.3%、97.4%);ypT3、YPmB期患者DFS较差(分别为70.2%和46.7%)。淋巴结阴性和阳性患者的DFS差异显著(分别为96.8%、58.5%,X2=34.125,P=0.000);是否存在局部浸润因素患者的DFS分别为42.9%、90.1%,差异亦有统计学意义(X2=32.666,P=0.000)。多因素分析显示N分期(RR=12.312,95%cI:2.828~39.258,P=0.000)和局部浸润因素(RR=5.422,95%CI:1.202-8.493,P=0.020)是DFS的独立预后指标。结论直肠癌新辅助治疗后的病理分期状况与患者的生存预后密切相关,ypT分期和ypTNM分期的进展预示患者预后不良;淋巴结状况和局部浸润因素是生存预后的独立危险因素。 Objective The present study assessed the pathological staging features of rectal cancer after neoadjuvant chemoradiotherapy, and its relation to prognosis. Methods Pathologic data related to TNM classification were analyzed on the surgical specimens of 135 patients with mid-low rectal cancer after neoadjuvant themoradiotherapy from 2005 to 2012. Tumor invasion, nodal status, local invasive factors (including cancer deposit, radial margin, perivascular or perineural invasion ) were investigated with patients' 3-year disease-free survival (DFS). Results The overall 3-year DFS was 85.2%, with a pathological complete response (pCR) rate of 19. 26%. Three out of 29 patients (10.4%) with ypT0 were found to have positive lymph nodes. There was a trend towards decreased survival as the ypT category and ypTNM staging increased ( X2 = 14. 296 and 52. 643, P = 0. 006 and 0. 000). ypT0-T2 in T category and ypO-I in TNM staging showed a favorable survival above 92% , while the patients with ypT3, or ypm B had a comparable lower DFS of 70. 2% and 46. 7%. DFS in patients with negative lymph node were significantly improved than those with positive nodes (93.5% vs. 66. 7%, ~2 =34. 125, P =0. 000). Patients with or without local invasive factor significantly differed in DFS (42. 9% vs. 90. 1%, ~2 =32. 666, P =0. 000). Cox regression analyze showed that the nodal status (RR = 12. 312, 95% CI: 2. 828-39. 258, P =0. 000) and local invasive factors (RR = 5. 422, 95% CI: 1. 202-8. 493, P = 0. 020) were independent risk factorsto 3-year survival. As the concept of clinical complete response (cCR) is obscure, there were 27.6% of patients with ypTO had normal mucosa or no evidence of tumor by EUS or MRI tests before surgery. Conclusion Postoperative pathologic staging features were closely associated with patient's prognosis. The increasing of ypT or ypTNM staging was correlated to decreasing of DFS. Nodal status, positive radial margin, perivascular and perineural invasion were independent risk factors to DFS. Since cCR did not correlate and could not predict pCR, the ongoing radical surgery could not be avoided even there was no evidence of tumor existin~ before oneration.
出处 《中华外科杂志》 CAS CSCD 北大核心 2014年第2期99-104,共6页 Chinese Journal of Surgery
关键词 直肠肿瘤 肿瘤分期 抗肿瘤联合化疗方案 放射疗法 Rectal neoplasms Neoplasm staging Antineoplastic combined chemotherapy protocols Radiotherapy
  • 相关文献

参考文献25

  • 1Maas M, Nelemans PJ, Valentini V, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data [ J]. Lancet Oncol, 2010, 11 (9) : 835-844.
  • 2Edge SB, Byrd DR, Compton CC, et al. AJCC Cancer Staging Manual. Colon and Rectum [ M:. Chicago: Springer, 2010.
  • 3王保华,张冠南,肖毅,吴斌,林国乐,崔全才,胡克,仲光熙,邱辉忠.新辅助治疗对进展期直肠癌术后淋巴结获取数目的影响[J].中华外科杂志,2009,47(23):1779-1783. 被引量:7
  • 4Sauer R, Liersch T, Merkel S, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: Results of the German CAO/ARO/AIO-94 randomized phase :I trial after a median follow-up of 11 years [ J :. J Clin Oneol, 2012, 30 (16) : 1926-1933.
  • 5Aschele C, Cionini L, Lonardi S, et aL Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-O1 randomized phase :[ trial [J]. J Clin Oncol, 2011, 29 (20) : 2773-2780.
  • 6G6rard JP, Azria D, Gourgou-Bourgade S, et at. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase 11I trial ACCORD 12/0405- Prodige 2 [J]. J Clin Oncol, 2010, 28 (10) : 1638:1644.
  • 7Roh MS, Yothers GA, O' Connell MJ, et al. The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04 [J]. J Clin Oncol, 2011, 29 (Suppl): abstr 3503. http:// meetinglibrary, asco. org/comtent/76910-102.
  • 8R:del C, Liersch T, Becker H, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/ AIO-04 randomised phase 3 trial [ J]. Lancet Oncol, 2012, 13 (7) : 679-687.
  • 9吴斌,邱辉忠,肖毅,林国乐,牛备战,张福泉,胡克.直肠癌患者术前联合放疗化疗与单纯放疗的疗效比较[J].中华胃肠外科杂志,2008,11(2):124-127. 被引量:12
  • 10Moon SH, Kim DY, Park JW, et al. Can the new American Joint Committee on Cancer staging system predict survival in rectal cancer patients treated with curative surgery following preoperative chemoradiotherapy? [ Jl. Cancer, 2012, 118 (20) : 4961-4968.

二级参考文献35

  • 1郁宝铭,吴唯勤.新辅助化放疗与TME联合治疗局部进展期低位直肠癌[J].中国实用外科杂志,2005,25(5):270-272. 被引量:56
  • 2Rou B, Sturm I, Lage H, et al. Dynamic expression profile of p21 and Ki-67 predicts survival in rectal carcinoma treated with preoperative radiochemotherapy. J Clin Oncol, 2003,21: 3391-3401.
  • 3Kapiteijn E, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med, 2001,345:638-646.
  • 4Collette L, Bosset JF, den Dulk M, et al. Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group. J Clin Oncol, 2007,25:4339-4340.
  • 5Burton S, Brown G, Daniels IR, et al. MRI directed muhidisciplinary team preoperative treatment strategy : the way to eliminate positive circumferential margins? Br J Cancer, 2006,94 : 351-357.
  • 6Crane CH, Skibber JM, Birnbaum EH, et al. The addition of continuous infusion 5-FU to preoperative radiation therapy increases tumor response, leading to increased sphincter preservation in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys, 2003,57 : 84-89.
  • 7Gerard JP, Conroy T, Bonnetain F, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol, 2006,24 : 4620-4625.
  • 8Ryan DP, Niedzwiecki D, Hollis D, et al. Phase Ⅰ/Ⅱ study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901. J Clin Oncol, 2006,24 : 2557-2562.
  • 9Willeke F, Horisberger K, Kraus-Tiefenbacher U, et al. A phase Ⅱ study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer. Br J Cancer,2007,96:912-917.
  • 10Machiels JP, Sempoux C, Scalliet P, et al. Phase Ⅰ /Ⅱ study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer. Ann Oncol, 2007, 18 : 738-744.

共引文献31

同被引文献93

  • 1Francesca De Felice,Daniela Musio,Luciano Izzo,Vincenzo Tombolini.Neoadjuvant chemoradiotherapy for locally advanced rectal cancer:The debate continues[J].World Journal of Gastrointestinal Oncology,2014,6(12):438-440. 被引量:5
  • 2Ming Li Jin Gu.Changing patterns of colorectal cancer in China over a period of 20 years[J].World Journal of Gastroenterology,2005,11(30):4685-4688. 被引量:93
  • 3Edge SB, Byrd DR, Compton CC, et al. AJCC Cancer Staging Manual [M]. Chicago,IL:Springer, 2010.
  • 4Das P, Skibber JM, Rodriguez-Bigas MA, et al. Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer [J]. Cancer, 2007,109: 1750-1755.
  • 5Qiu HZ, Wu B, Xiao Y, et al. Combination of differentiation and T stage can predict unresponsiveness to neoadjuvant therapy for rectal cancer [J]. Coloreetal Dis, 2011,13:1353- 1360.
  • 6Arredondo J, Baixanli J, Beorlegui C, et al. Prognosis factors for recurrence in patients with locally advanced rectal cancer preoperatively treated with chemoradiotherapy and adjuvant chemotherapy [J]. Dis Colon Rectum, 2013,56:416-421.
  • 7Roy P, Serra S, Kennedy E, et al. The prognostic value of grade of regression and oncocytic change in rectal adenocarcinoma treated with neo-adjuvant chemoradiotherapy [J]. J Surg Oneol, 2012,105 : 130-134.
  • 8Kim TH, Chang H J, Kim DY, et al. Pathologic nodal classification is the most discriminating prognostic factor for disease-free survival in rectal cancer patients treated with pre- operative chemoradiotherapy and curative resection [J]. Int J Radiat Oncol Biol Phys, 2010,77:1158-1165.
  • 9Rodel C, Martus P, Papadoupolos T, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer [J]. J Clin Oncol, 2005, 23 : 8688-8696.
  • 10Mohiuddin M, Paulus R, Mitchell E, et al. Neoadjuvantchemoradiation for distal rectal cancer: 5-year updated results of a randomized phase 2 study of neoadjuvant combined modality chemoradiation for distal rectal cancer [J]. Int J Radiat Oncol Biol Phys, 2013,86:523-528.

引证文献13

二级引证文献70

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部